Jane otezla and jeron teng biography
•
Min Qiu, Jiahuan Li, Shali Hao, Haoxiao Zheng, Xiaojie Zhang, Hailan Zhu, Xiaolin Zhu, Yunzhao Hu, Xiaoyan Cai, Yuli Huang. Non-alcoholic fatty liver disease is associated with a worse prognosis in patients with heart failure: A pool analysis. Frontiers in Endocrinology 2023; 14 doi: 10.3389/fendo.2023.1167608
Flavia Vernin de Oliveira Terzi, Gabriel Cordeiro Camargo, Daniella Braz Parente, Ana Maria Pittella, Gilberto Silva-Junior, Gabrielle Gonçalves de Novaes, Jaime Araújo Oliveira Neto, Julia Machado Barroso, Martha Valéria Tavares Pinheiro, Adriana Soares Xavier de Brito, Renée Sarmento de Oliveira, Rosana Souza Rodrigues, Renata de Mello Perez, Andréa Silvestre de Sousa, Renata Junqueira Moll-Bernardes. How Cardiac Fibrosis Assessed via T1 Mapping Is Associated with Liver Fibrosis in Patients with Non-Alcoholic Fatty Liver Disease. Journal of Clinical Medicine 2023; 12(23): 7381 doi: 10.3390/jcm12237381
•
Research for Rare - Research for rare diseases
28. January 2025 (HiChol)
Comparison of different microbiome analysis pipelines to validate their reproducibility of gastric mucosal microbiome composition
mSystems. 2025 Jan 28. >>Pubmed-Link<<
Konrad Lehr, Baptiste Oosterlinck, Chee Kin Then, Matthew R Gemmell, Rolandas Gedgaudas, Jan Bornschein, Juozas Kupcinskas, Annemieke Smet, Georgina Hold, Alexander Link; ENIGMA: European Network for the Investigation of Gastrointestinal Mucosal Alterations
28. January 2025 (ADDRess)
Cancer risk in carriers of TP53 germline variants grouped into different functional categories
JNCI Cancer Spectr. 2025 Jan 28. >>Pubmed-Link<<
Lucas John Müntnich, Christina M Dutzmann, Anika Großhennig, Valentina Härter, Myriam Keymling, Angela Mastronuzzi, Emilie Montellier, Juliane Nees, Natalie E Palmaers, Judith Penkert, Stefan M Pfister, Tim Ripperger, Sarah Schott, Farina Silchmüller, Pierre Ha
•
Content Posted in 2020
Link
1020O A phase inom, first-in-human, open-label, dose escalation study of MGD019, an investigational bispecific PD-1 x CTLA-4 DART® molecule in patients with advanced solid tumours, M Sharma, Rachel E Sanborn, GM Cote, JC Bendell, S Kaul, F Chen, A Berezhnoy, P Moore, E Bonvini, BJ Sumrow, and JJ Luke
Link
1074TiP SGNTGT-001: A phase I study of SGN-TGT, an effector-function enhanced monoclonal antibody (mAb), in advanced malignancies, E Garralda, Rachel E Sanborn, AR Minchom, D Davar, G Curigliano, V Ribrag, A Mehta, F Foss, P Garfin, and S Ansell
Link
1258O Amivantamab (JNJ-61186372), an EGFR-MET bispecific antibody, in combination with lazertinib, a 3rd-generation tyrosine kinase inhibitor (TKI), in advanced EGFR NSCLC, BC Cho, KH Lee, EK Cho, D-W Kim, J-S Lee, J-Y Han, S-W Kim, A Spira, EB Haura, EK Sabari, Rachel E Sanborn, JM Bauml, JE Gomez, P Lorenzini, JR Infante, J Xie, N Haddish-Berhane, M Thayu, RE Knoblauch, and K Park
Link
154 Marrow-infi